BioCentury
ARTICLE | Clinical News

Pharmalink's Nefecon meets nephropathy endpoint

April 15, 2015 2:18 AM UTC

Pharmalink AB (Stockholm, Sweden) stopped the Phase IIb NEFIGAN trial early after an interim analysis showed Nefecon ( PL-56) met the primary endpoint to treat IgA nephropathy.

Daily administration of Nefecon led to statistically significant improvement over placebo in mean reduction in urine protein creatinine ratio (UPCR) over a nine-month treatment period (p=0.0066). The European trial enrolled over 150 IgA nephropathy patients with persistent proteinuria despite optimized standard-of-care therapy. ...